Tianlei Wang,1,2,* Xinrui Bao,1,2,* Fang Yang,1,2 Shenbin Pan,1,2 Ke Xu,1,2 Tao Ren1,2 

1Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, People’s Republic of China; 2Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Ke Xu; Tao Ren, Email xuke@cmc.edu.cn; rentao509@cmc.edu.cn

Background: COL10A1 expression was up-regulated and could promote tumor development in pancreatic cancer. As a secreted protein, plasma COL10A1 level was proven to have certain diagnostic efficacy in gastric cancer, breast cancer, and colorectal cancer. It is still unknown whether it has a biomarker role for pancreatic cancer.
Aim: To explore and analyze the diagnostic and prognostic value of plasma COL10A1 level in pancreatic ductal adenocarcinoma (PDAC).
Method: The RNA-seq dataset of PDAC from The Cancer Genome Atlas (TCGA) and six expression profiling microarray datasets from Gene Expression Omnibus (GEO) were downloaded to analyze the expression of COL10A1 in tissues. Thirty-six patients with PDAC and eighteen healthy volunteers were enrolled to measure COL10A1 levels in tissues and plasmas, and the relationship between clinical characteristics and the COL10A1 levels was analyzed. The diagnostic and prognostic efficacy of plasma COL10A1 levels were calculated.
Results: Aspects of COL10A1 expression level in tissues, COL10A1 expression was significantly higher in PDAC tissue than adjacent normal tissue. The expression of COL10A1 was correlated with T, M, and AJCC stages. Patients with high COL10A1 expression had worse recurrence-free survival (RFS) and overall survival (OS) than those with low expression. Aspects of COL10A1 expression levels in plasma, its diagnostic area under the curve (AUC) for PDAC was 0.926 (95% CI 0.853– 0.999), diagnostic sensitivity was 81% (95% CI 64– 92%), and specificity was 100% (95% CI 81– 100%). The time-dependent AUCs at 1-year and 3-year were 0.71 (95% CI 0.51– 0.90) and 0.74 (95% CI 0.48– 1.00), respectively.
Conclusion: In PDAC, plasma COL10A1 levels showed certain diagnostic and prognostic efficacy. COL10A1 may be a diagnostic and prognostic biomarker for PDAC and play a role in liquid biopsy of this disease.

Keywords: COL10A1, pancreatic ductal adenocarcinoma, biomarkers, diagnosis, prognosis